Abstract
Introduction
Leukocyte adhesion deficiency (LAD) type III is a rare syndrome characterized by severe recurrent infections, leukocytosis, and increased bleeding tendency. All integrins are normally expressed yet a defect in their activation leads to the observed clinical manifestations.
Materials and Methods
Less than 20 patients have been reported world wide and the primary genetic defect was identified in some of them. Here we describe the clinical features of patients in whom a mutation in the calcium and diacylglycerol-regulated guanine nucleotide exchange factor 1 (CalDAG GEF1) was found and compare them to other cases of LAD III and to animal models harboring a mutation in the CalDAG GEF1 gene.
Discussion
The hallmarks of the syndrome are recurrent infections accompanied by severe bleeding episodes distinguished by osteopetrosis like bone abnormalities and neurodevelopmental defects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Etzioni A, Harlan JM. Cell adhesion and leukocyte adhesions defects. In: Smith EM, Puck J, Ochs HD eds. Primary Immune deficiency disease. A molecular and genetic approach, 2nd ed. Oxford University Press; 2007. p. 550–64.
Hogg N, Stewart MP, Scarth SL, Newton R, Shaw JM, Law SK, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins MAC-1 and LFA-1. J Clin Invest 1999;103:97–106. doi:10.1172/JCI3312.
Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, Paulson JC, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 1992;327:1789–92.
Lubke T, Marquardt T, Etzioni A, Hatmann E, von Figura K, Korner C. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat Genet 2001;28:73–6. doi:10.1038/88299.
Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301–14. doi:10.1016/0092-8674(94)90337-9.
McDowall A, Inwald D, Leitinger B, Jones A, Liesner R, Klein N, et al. A novel form of integrin dysfunction involving beta 1, beta 2 and beta 3 integrings. J Clin Invest 2003;111:51–60.
Harris ES, Shigeoka AO, Li W, Adams RH, Prescott SM, McIntyre TM, et al. A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by beta 1 and beta 2 integrins. Blood 2001;97:767–76. doi:10.1182/blood.V97.3.767.
Alon R, Aker M, Feigelson S, Sokolowsky-Eisenberg M, Stauton D, Cinamon G, et al. A novel genetic leukocyte adhesion deficiency in sub-second triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow. Blood 2003;101:4437–45.
Alon R, Etzioni A. Lad III, a novel group of leukocyte integrin activation deficiencies. Trends Immunol 2003;24:561–6. doi:10.1016/j.it.2003.08.001.
Kinashi T. intracellular signaling controlling integrin activation in lymphocytes. Nat Rev Immunol 2005;5:546–59. doi:10.1038/nri1646.
Pasvolsky R, Felgelson SW, Kilic SS, Simon AJ, Tal-Lapidot G, Grabovsky V, et al. LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEF1 in lymphocyted, neutrophils and platelets. J Exp Med 2007;204:1571–82.
Ginsberg MH, Partridge A, Shattil SJ. Integrinregulation. Curr Opin Cell Biol 2005;17:509–16. doi:10.1016/j.ceb.2005.08.010.
Nurden P, Nurden AT. Congenital disorders associated with platelets dysfunctions. Thromb Haemost 2008;99:253–63.
Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, et al. CalDAG GEF1 integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004;10:982–6. doi:10.1038/nm1098.
Kuijpars TW, van Brudden R, Kamerbeek N, Tool ATJ, Hicsonmez G, Gurgey A, et al. Natural history and early diagnosis of LAD-1/variant. Blood 2007;109:3529–37. doi:10.1182/blood-2006-05-021402.
Kawasaki H, Springett GM, Toki S, Canales JJ, Harlan P, Blumenstiel JP, et al. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci U S A 1998;95:13278–83. doi:10.1073/pnas.95.22.13278.
Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, et al. Osteoclast poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Gen 2007;39:960–2.
Teitelbaum SL. Osteoclasts:What do they do and how do they do it? Am J Pathol 2007;170:427–35. doi:10.2353/ajpath.2007.060834.
Bergmeier W, George T, Wang HW, Crittenden JR, Baldwin ACW, Cifuni SM, et al. Mice lacking the signaling molecule CalDAG-GEF1 present a model for leukocyte adhesion deficiency type III. J Clin Invest 2007;117:1699–707. doi:10.1172/JCI30575.
Boudreaux MK, Schmutz SM, French PS. Calcium diacylglycerol guanine nucleotide exchange factor I (CalDAG-GEF1) gene mutations in a thrombopathic Simmental calf. Vet Pathol 2007;44:932–5. doi:10.1354/vp.44-6-932.
Boudreaux MK, Catalfamo JL, Klok M. Calcium in factor I gene mutations associated with loss of function in canine platelets. Trans Res 2007;150:81–92. doi:10.1016/j.trsl.2007.03.006.
Acknowledgement
We would like to thank Prof. Alon for critically reviewing the paper and to Prof. Rechavi’s group for helping in the genetic analysis of the families.
Recently we found that these patients have also mutation in Kindlin 3 (Blood Accepted).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kilic, S.S., Etzioni, A. The Clinical Spectrum of Leukocyte Adhesion Deficiency (LAD) III due to Defective CalDAG-GEF1. J Clin Immunol 29, 117–122 (2009). https://doi.org/10.1007/s10875-008-9226-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-008-9226-z